SCHEMBL3354775

SCHEMBL3354775

COc1cccc(CNC[C@H](O)[C@H](Cc2ccccc2)NC(=O)N(c2ccccc2)c2ccccc2)c1

nearest known ligand 0.71

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.69
CTSD P07339 14/20 0.66
BACE1 P56817 15/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3354770 1.00 BCHE (0.69) BCHECTSDBACE1
SCHEMBL3351385 0.92 BCHE (0.69) BCHECTSDBACE1
SCHEMBL3351378 0.92 BCHE (0.69) BCHECTSDBACE1
SCHEMBL3348050 0.90 BCHE (0.72) BCHECTSDBACE1
SCHEMBL3348045 0.90 BCHE (0.72) BCHECTSDBACE1
SCHEMBL3351995 0.88 BCHE (0.69) BCHECTSDBACE1
SCHEMBL3352004 0.88 BCHE (0.69) BCHECTSDBACE1
SCHEMBL3354218 0.87 BCHE (0.77) BCHECTSDBACE1
SCHEMBL6896962 0.87 BCHE (0.77) BCHECTSDBACE1
SCHEMBL3354210 0.87 BCHE (0.77) BCHECTSDBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed
US-7176242-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP BCHE 17/4885CTSD 96/4885BACE1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.